Phase 2 RCT: Glycemic control similar between one-weekly basal insulin Fc and once-daily degludec in insulin-naïve T2D
In this medfyle
Basal insulin may be needed in people with type 2 diabetes, but many patients and clinicians are reluctant to begin therapy – in part due to the fear of injection burden. These clinical trial results with a novel once-weekly insulin suggest excellent glycemic control, and could represent an exciting new option.
About this Medfyle
©2023 Medfyle. All rights reserved.
Original article: Bue-Valleskey JM, Kazda CM, Ma C, Chien J, Zhang Q, Chigutsa E, Landschulz W, Haupt A, Frias JP. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care. 2023 May 1;46(5):1060-1067. doi: 10.2337/dc22-2396. PMID: 36944059; PMCID: PMC10154646.
The summary content was prepared by Marie Farrow for Medfyle, and reviewed by Marco Comoglio, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
